Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes.

Jacobson PB, von Geldern TW, Ohman L, Osterland M, Wang J, Zinker B, Wilcox D, Nguyen PT, Mika A, Fung S, Fey T, Goos-Nilsson A, Grynfarb M, Barkhem T, Marsh K, Beno DW, Nga-Nguyen B, Kym PR, Link JT, Tu N, Edgerton DS, Cherrington A, Efendic S, Lane BC, Opgenorth TJ
J Pharmacol Exp Ther. 2005 314 (1): 191-200

PMID: 15784656 · DOI:10.1124/jpet.104.081257

MeSH Terms (27)

3T3 Cells Adipocytes Animals Biotransformation Blood Glucose Cell Differentiation Cholic Acids Diabetes Mellitus, Type 2 Dogs Drug Synergism Estrone Glucocorticoids Glucose Glutamate-Ammonia Ligase Hypoglycemic Agents Liver Male Mice Obesity Prednisolone Rats Rats, Zucker Receptors, Glucocorticoid Reverse Transcriptase Polymerase Chain Reaction Rosiglitazone Thiazolidinediones Tyrosine Transaminase

Connections (2)

This publication is referenced by other Labnodes entities: